WST · US market
West Pharmaceutical Services Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$25.69bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- US$564.90m
- Latest-quarter run-rate earnings
- US$616.00m
- Latest fiscal-year earnings
- US$493.70m
- Trailing revenue
- US$3.33bn
- Latest-quarter run-rate revenue
- US$3.49bn
- Latest fiscal-year revenue
- US$3.07bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- VRMCX · Virtus KAR Mid-Cap Core Fund Class R65.33% weight · Holdings dated 30 June 2026
- PHSKX · Virtus KAR Mid-Cap Growth Fund Class A4.80% weight · Holdings dated 30 June 2026
- ARTMX · Artisan Mid Cap Fund Investor Class3.78% weight · Holdings dated 30 June 2026
- WAUSX · Wasatch U.S. Select Fund Investor Class3.66% weight · Holdings dated 30 June 2026
- CCSMX · Conestoga SMid Cap Fund Investors Class3.26% weight · Holdings dated 30 June 2026
- RMBMX · RMB SMID Cap Fund Class I3.20% weight · Holdings dated 30 June 2026
- FSMEX · Fidelity Select Medical Technology and Devices Portfolio3.09% weight · Holdings dated 31 May 2026
- BAGAX · Brown Advisory Growth Equity Fund Advisor Shares3.00% weight · Holdings dated 30 June 2026
- CSIEX · Calvert Equity Fund Class A2.95% weight · Holdings dated 30 June 2026
- BASG · Brown Advisory Sustainable Growth ETF2.95% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.